Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Abstract: In an apparatus and method for generating a three-dimensional representation from a two-dimensional image, a memory device stores information for processing a two-dimensional image and for generating a three-dimensional image from the two-dimensional image, a processing device processes a digital representation of an image by generating a two-dimensional image from the digital representation and by generating a three-dimensional image corresponding to the two-dimensional image, and an output device outputs a three-dimensional image and a digital signal representation of the three-dimensional image.

Abstract: In an apparatus and method for generating a three-dimensional representation from a two-dimensional image, a memory device stores information for processing a two-dimensional image and for generating a three-dimensional image from the two-dimensional image, a processing device processes a digital representation of an image by generating a two-dimensional image from the digital representation and by generating a three-dimensional image corresponding to the two-dimensional image, and an output device outputs a three-dimensional image and a digital signal representation of the three-dimensional image.

Abstract: In a system and method for generating a 3-dimensional representation of a portion of an organism, collecting training data, wherein the training data includes a first set of training data and a second set of training data. At least one statistical model having a set of parameters is built using the training data. The at least one statistical model is compared to a 2-dimensional image of the portion of the organism. At least one parameter of the set of parameters of the statistical model is modified based on the comparison of the at least one statistical model to the 2-dimensional image of the portion of the organism. The modified set of parameters representing the portion of the organism is passed through the statistical model.

Abstract: This invention relates to air breathing engines, such as ramjets, scramjets and internal combustion, and more particularly to an active combustion control device for a combustor. In more particularity, the present invention relates to a method and apparatus that applies active combustion control technology to advanced propulsion devices and closed-loop fuel injection at sub-harmonic frequencies of the instability frequency of the combustor. The problem of limited actuator frequency response is addressed by injecting fuel pulses at sub-harmonic frequencies of the instability. The fuel may be liquid, solid or gas. To achieve this desired result, a closed loop controller is designed to determine sub-harmonic frequencies using a divider to divide the instability frequency of a combustor, yielding a fraction of the harmonic frequency.

Abstract: This invention relates to air breathing engines, such as ramjets, scramjets and internal combustion, and more particularly to an active combustion control device for a combustor. In more particularity, the present invention relates to a method and apparatus that applies active combustion control technology to advanced propulsion devices and closed-loop fuel injection at sub-harmonic frequencies of the instability frequency of the combustor. The problem of limited actuator frequency response is addressed by injecting fuel pulses at sub-harmonic frequencies of the instability. The fuel may be liquid, solid or gas. To achieve this desired result, a closed loop controller is designed to determine sub-harmonic frequencies using a divider to divide the instability frequency of a combustor, yielding a fraction of the harmonic frequency.

Abstract: This invention relates to air breathing engines, such as ramjets, scramjets and internal combustion, and more particularly to an active combustion control device for a combustor. In more particularity, the present invention relates to a method and apparatus that applies active combustion control technology to advanced propulsion devices and closed-loop fuel injection at sub-harmonic frequencies of the instability frequency of the combustor. The problem of limited actuator frequency response is addressed by injecting fuel pulses at sub-harmonic frequencies of the instability. The fuel may be liquid, solid or gas. To achieve this desired result, a closed loop controller is designed to determine sub-harmonic frequencies using a divider to divide the instability frequency of a combustor, yielding a fraction of the harmonic frequency.